A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Our diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. They can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in extremely small concentrations. Our products are designed to enhance the health and well-being of people, while reducing total healthcare cost. Our extensive range of medical diagnostic products is sold worldwide, primarily in two markets: clinical laboratories and point-of-care settings. Most of our products are Conformite Europeenne (“CE”) marked and/or registered with regulatory agencies in various countries for diagnostic use, with several also cleared by the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 4.5M | 5.3M | 5.4M | 5.3M | 19M | 7.2M |
| Net Income | -4.0M | -5.0M | -6.0M | -7.1M | -4.5M | -7.4M |
| EPS | $-1.60 | $-2.16 | $-22.72 | $-4.00 | $-2.88 | $-4.96 |
| Free Cash Flow | 0 | -3.9M | -5.4M | -5.5M | -536K | -5.4M |
| ROIC | -68.9% | -98.9% | -76.3% | -71.2% | -43.0% | -63.5% |
| Gross Margin | 5.6% | 9.4% | 11.3% | 8.4% | 15.8% | 5.1% |
| Debt/Equity | 0.00 | 0.45 | 0.40 | 0.23 | 0.37 | 0.28 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -5.3M | -5.1M | -6.4M | -7.2M | -4.5M | -7.5M |
| Operating Margin | -118.1% | -96.7% | -117.6% | -135.3% | -24.0% | -104.2% |
| ROE | -90.8% | -93.0% | -65.3% | -71.2% | -51.6% | -63.5% |
| Shares Outstanding | 3M | 2M | 0M | 2M | 2M | 2M |
BIOMERICA INC passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 10.0%.
BIOMERICA INC (BMRA) has a 5-year average return on invested capital (ROIC) of -70.6%. This is below average and may indicate limited pricing power.
BIOMERICA INC (BMRA) has a market capitalization of $6M. It is classified as a small-cap stock.
BIOMERICA INC (BMRA) does not currently pay a regular dividend.
BIOMERICA INC (BMRA) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
BIOMERICA INC (BMRA) reported annual revenue of $5 million in its most recent fiscal year, based on SEC EDGAR filings.
BIOMERICA INC (BMRA) has a net profit margin of -93.6%. The company is currently unprofitable.
BIOMERICA INC (BMRA) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
BIOMERICA INC (BMRA) has a debt-to-equity ratio of 0.45. This indicates a conservatively financed balance sheet.
BIOMERICA INC (BMRA) reported earnings per share (EPS) of $-2.16 in its most recent fiscal year.
BIOMERICA INC (BMRA) has a return on equity (ROE) of -93.0%. A negative ROE may indicate losses or negative equity.
BIOMERICA INC (BMRA) has a 5-year average gross margin of 10.0%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 15 years of financial data for BIOMERICA INC (BMRA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BIOMERICA INC (BMRA) has a book value per share of $1.78, based on its most recent annual SEC filing.
No recent press releases.